KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned a consensus rating of "Buy" from the nine analysts that are covering the firm, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $26.2857.

KALV has been the topic of several research reports. Leerink Partners boosted their price target on shares of KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, July 7th. JMP Securities boosted their price target on shares of KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Tuesday, July 8th. Finally, HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th.

KalVista Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ KALV opened at $13.34 on Tuesday. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $16.32. The firm's 50-day simple moving average is $13.44 and its 200 day simple moving average is $12.27. The stock has a market cap of $666.39 million, a P/E ratio of -3.62 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last issued its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the company posted ($1.07) EPS. On average, sell-side analysts anticipate that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares in the company, valued at approximately $5,798,945.55. The trade was a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders sold 42,294 shares of company stock worth $645,662. 10.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of KALV. Tower Research Capital LLC TRC grew its stake in shares of KalVista Pharmaceuticals by 816.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company's stock valued at $91,000 after buying an additional 7,180 shares in the last quarter. Rafferty Asset Management LLC grew its stake in shares of KalVista Pharmaceuticals by 78.5% in the 2nd quarter. Rafferty Asset Management LLC now owns 46,901 shares of the specialty pharmaceutical company's stock valued at $530,000 after buying an additional 20,632 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $151,000. Finally, Bank of America Corp DE grew its stake in shares of KalVista Pharmaceuticals by 19.0% in the 2nd quarter. Bank of America Corp DE now owns 366,966 shares of the specialty pharmaceutical company's stock valued at $4,149,000 after buying an additional 58,719 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.